Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Posner, Marshall R.a; b; | Elboim, Hillary S.a | Tumber, Marea B.a | Wiest, Peter M.d | Tibbetts, Lance M.c
Affiliations: [a] Human Monoclonal Antibody Laboratory | [b] Department of Medicine | [c] Department of Pathology, Roger Williams General Hospital | [d] Department of Medicine, Miriam Hospital; and the Departments of Medicine and Pathology, Brown University Medical School, Providence, Rhode Island, USA
Note: [] Address reprint requests to Marshall R. Posner, MD, at his present address: New England Deaconess Hospital, 185 Pilgrim Road, Boston, MA 02215, USA. A version of this paper was presented at the First International Conference on Human Antibodies and Hybridomas, 18–20 April 1990, Orlando, FL, USA.
Abstract: A human IgG3 monoclonal antibody (HMab), F86, that reacts with breast cancer cells was obtained by fusion of antibody-secreting Epstein-Barr virus (EBV)-transformed cells from a draining lymph node with the human fusion partner HMMA2.11TG/O. F86 reacts with an antigen expressed on the surface offive malignant human breast cancer cell lines and several human malignant myelomonocytic cell lines but is not detected on normal peripheral blood mononuclear cells. Studies with tissue sections of a human breast cancer line xenografted in nude mice have demonstrated that the F86 antigen is expressed both on the cell surface and in the cytoplasm of tumor cells. The F86 antigen is also expressed by the tumor cells in the original tumor specimen of a patient from whom one of the test cell lines and the xenografts were derived. Functionally, the F86 antibody does not mediate complement lysis or antibody-dependent cellular cytotoxicity in vitro. The F86 antigen could not be labeled by [35S]methionine or 125I and immunoprecipitated. The nature and expression of antigens such as that detected by the HMab F86 and how they became immunogenic and/or suppress an active immune response can be addressed through the use of HMab.
Keywords: monoclonal antibodies, breast cancer, Epstein-Barr virus, IgG, surface membrane antigens
DOI: 10.3233/HAB-1991-2205
Journal: Human Antibodies, vol. 2, no. 2, pp. 74-83, 1991
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]